16.00
-1.5(-8.57%)
Currency In GBp
Address
1 Springbank Road
Belfast, BT17 0QL
United Kingdom of Great Britain and Northern Ireland
Phone
44 28 9043 2800
Sector
Healthcare
Industry
Biotechnology
Employees
27
First IPO Date
December 18, 2017
| Name | Title | Pay | Year Born |
| Dr. Adrian Robert Kinkaid Ph.D. | Chief Executive Officer & Director | 179,000 | 1967 |
| Dr. Richard John Buick Ph.D. | Chief Scientific Officer & Director | 122,000 | 1976 |
| Ms. Nicola Hamilton | Operations Manager | 0 | N/A |
| Prof. Jim Johnston Ph.D. | Founder | 0 | N/A |
| Mr. Stephen Barry Smyth | Company Secretary, Interim Chief Financial Officer & Director | 0 | 1974 |
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
